IHP-102 / IHP Therapeutics - LARVOL DELTA

IHP-102 reduces pain and modulates complement activation in a sickle cell mouse model (ASH 2025) - "Disease modifying agents like hydroxyureamay reduce the frequency of pain events in responders, but there is an urgent need for interventionsthat can modify the course of a VOE once it has started. HbSS mice exhibited robust acute hypoxia-induced pain behaviors, including increased pawwithdrawal frequency (PWF) to von Frey filaments (0.16 and 1.0g) and increased cold plate responses,indicating mechanical allodynia and hyperalgesia, and cold hyperalgesia. Rescue administration of IHP-102 (3 and 10 mg/kg) significantly reduced PWF from 0.16g filament at 4- and 24-hours post-hypoxia.While 10 mg/kg IHP-102 reduced PWF to 1.0g von Frey filament at 1, 4, and 24 hours, 3 mg/kg was onlyeffective at 4 hours. In the cold plate test, 3 and 10 mg/kg significantly reduced the number of coldresponses in HbSS mice at 1, 4, and 24 hours."

Preclinical • Genetic Disorders • Hematological Disorders • Pain • Sickle Cell Disease

IHP-102 compound decreases the adhesion of sickle cell disease RBCs to acutely activated endothelial cells in biochip labs endothelial-on-a-chip assay (ASH 2025) - "IHP-102 inhibits RBC adhesion to acutely activated HUVECs across a diverse dosagespectrum from 100μg/mL down to 1μg/mL. These results further support its potential as an acutetreatment for VOE and are a first demonstration of its activity in human SCD donor blood. Our findingsindicate that IHP-102 exhibits increased effectiveness when the baseline adhesion level is elevated due toheterogeneity in SCD."

Genetic Disorders • Hematological Disorders • Sickle Cell Disease

Dual complement and P-selectin inhibitor, IHP-102, prevents lung vaso-occlusion in P-selectin-deficient townes SS mice (ASH 2025) - "In contrast, the polypharmacologic activity of IHP-102 demonstrates strong therapeutic potential with profound benefit beyond P-selectin inhibition.Additionally, IHP-102 is dosed by SC route and can therefore be self-administered in the ambulatorysetting, thus circumventing a largely ill-equipped healthcare system that has plagued SCD care. IHP-102has the potential to transform management of VOE, offering significant relief from disease and theassociated debilitating pain and organ damage."

Preclinical • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • SELP

Dual P-Selectin and Complement Inhibition with Subcutaneous IHP-102 Treatment Potently Reduces Lung Vaso-Occlusion in Sickle Cell Disease Mice (ASH 2023) - "The dual anti-complement and anti-P-selectin activity of IHP-102, together with its potential for home-based treatment, offers great potential to fill a major treatment gap for acute VOE. Its potent in vivo activity suggests that this dual target approach could provide robust therapeutic benefit and warrants further investigation toward clinical trials."

Preclinical • Cardiovascular • Genetic Disorders • Hematological Disorders • Inflammation • Sickle Cell Disease

IHP-102 Reduces Hypoxia-Induced Pain Behaviors in Townes SCD Mice (ASH 2024) - "It is also likely that repeat administration may be needed, depending on VOE severity, potentially every 12 to 24 hours. With the successful completion of pre-clinical assessments and future clinical trials in individuals with SCD, IHP-102 has the potential to be a game-changing non-opioid, self-administrable VOE treatment option, allowing for at-home pain management by patients."

Preclinical • Genetic Disorders • Hematological Disorders • Movement Disorders • Pain • Sickle Cell Disease